Brandon Dickinson, MD
Gastroenterology · Provo, UTNPI 1770825713
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 355 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 34.8% of the total.
Across 355 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$662
- Johnson & Johnson$400
- Boston Scientific$328
- Pfizer$320
- Nestle Healthcare Nutrition Inc.$250
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,08899%
- Education$671%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 131 | $2,139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $662 |
| Johnson & Johnson | 20 | $400 |
| Boston Scientific | 3 | $328 |
| Pfizer | 38 | $320 |
| Nestle Healthcare Nutrition Inc. | 13 | $250 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $235 |
| Sanofi | 11 | $197 |
| Daiichi Sankyo Inc. | 8 | $162 |
| Aimmune Therapeutics, Inc. | 8 | $145 |
| Bristol Myers Squibb | 8 | $133 |
| Intercept Pharmaceuticals, Inc. | 8 | $133 |
| Organon | 9 | $122 |
| Gilead | 5 | $113 |
| Merck | 5 | $103 |
| QOL Medical, LLC | 4 | $93 |
| Madrigal Pharmaceuticals | 4 | $92 |
| Regeneron Healthcare Solutions, Inc. | 4 | $61 |
| Braintree Laboratories, Inc. | 1 | $45 |
| Ferring Pharmaceuticals Inc. | 3 | $42 |
| Celltrion USA Inc. | 2 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Lilly USA, LLC | 2 | $37 |
| Redhill Biopharma Inc. | 2 | $35 |
| Sandoz | 2 | $34 |
| Mylan Institutional Inc. | 1 | $30 |
| Boehringer Ingelheim | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Orphalan Inc | 1 | $27 |
| Fresenius Kabi USA, LLC | 1 | $26 |
| Romark Laboratories, LC | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AXIOS$142
- EXALT Model D$121
How this compares
$6,155 in reported general payments places this provider in the 80th percentile of 122 gastroenterology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 11 | $290,508 |
| Humira PenAdalimumab | 11 | $74,927 |
| CreonLipase/Protease/Amylase | 13 | $47,163 |
| ZenpepLipase/Protease/Amylase | 14 | $44,646 |
| XifaxanRifaximin | 11 | $33,035 |
| LinzessLinaclotide | 16 | $14,917 |
| Colestipol Hcl | 69 | $6,677 |
| Ursodiol | 29 | $6,244 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 47 | $5,827 |
| MovantikNaloxegol Oxalate | 11 | $5,578 |
| Omeprazole | 167 | $4,247 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 165 | $3,236 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 19 | $2,984 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 16 | $2,793 |
| Pantoprazole Sodium | 136 | $2,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $400 | $290,50811 claims |
| AbbVieCreon, Linzess | $2,139 | $62,08029 claims |
| Aimmune Therapeutics, Inc.Zenpep | $145 | $44,64614 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $235 | $33,03511 claims |
| Braintree Laboratories, Inc.Suflave, Sutab | $45 | $8,81166 claims |
| Redhill Biopharma Inc.Movantik | $35 | $5,57811 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $42 | $2,79316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 122 gastroenterology providers in Utah.
Other gastroenterology in Provo
- Chad KawaProvo$22K
- Brett ThorpeProvo$12K
- Kurt BodilyProvo$9K
- Bryce HaslemProvo$6K
- Thomas DickinsonProvo$4K
- Terry BoxSalt Lake City$302K
- Richard GilroySalt Lake City$192K
- Kyle EliasonOgden$128K
- Umaprasanna KarnamRiverton$120K
- Kathryn PetersonSalt Lake City$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.